PubMed:16135558 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":369,"end":375},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T2","span":{"begin":476,"end":487},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T3","span":{"begin":774,"end":791},"obj":"https://glytoucan.org/Structures/Glycans/G08371CD"},{"id":"T4","span":{"begin":774,"end":791},"obj":"https://glytoucan.org/Structures/Glycans/G36123IU"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":369,"end":375},"obj":"Glycan_Motif"},{"id":"T2","span":{"begin":476,"end":487},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":774,"end":791},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":781,"end":791},"obj":"Glycan_Motif"},{"id":"T6","span":{"begin":793,"end":796},"obj":"Glycan_Motif"},{"id":"T7","span":{"begin":1141,"end":1144},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY"},{"id":"A2","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G36123IU"},{"id":"A4","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G08371CD"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G57321FI"},{"id":"A6","pred":"image","subj":"T6","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G36123IU"},{"id":"A7","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G36123IU"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":557,"end":645},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":646,"end":809},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1245,"end":1435},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"T4","span":{"begin":557,"end":809},"obj":"Sentence"},{"id":"T5","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"T6","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"T7","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"T8","span":{"begin":1245,"end":1435},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"T4","span":{"begin":557,"end":645},"obj":"Sentence"},{"id":"T5","span":{"begin":646,"end":809},"obj":"Sentence"},{"id":"T6","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"T7","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"T8","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"T9","span":{"begin":1245,"end":1435},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":369,"end":375},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T2","span":{"begin":476,"end":487},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T3","span":{"begin":774,"end":791},"obj":"https://glytoucan.org/Structures/Glycans/G08371CD"},{"id":"T4","span":{"begin":774,"end":791},"obj":"https://glytoucan.org/Structures/Glycans/G36123IU"},{"id":"T5","span":{"begin":781,"end":791},"obj":"https://glytoucan.org/Structures/Glycans/G57321FI"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":774,"end":791},"obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"T2","span":{"begin":781,"end":791},"obj":"http://www.glycoepitope.jp/epitopes/EP0021"},{"id":"T3","span":{"begin":793,"end":796},"obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"T4","span":{"begin":1141,"end":1144},"obj":"http://www.glycoepitope.jp/epitopes/EP0022"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":212,"end":219},"obj":"HP_0002664"},{"id":"T2","span":{"begin":231,"end":244},"obj":"HP_0003002"},{"id":"T3","span":{"begin":231,"end":244},"obj":"HP_0100013"},{"id":"T4","span":{"begin":238,"end":244},"obj":"HP_0002664"},{"id":"T5","span":{"begin":578,"end":591},"obj":"HP_0003002"},{"id":"T6","span":{"begin":578,"end":591},"obj":"HP_0100013"},{"id":"T7","span":{"begin":585,"end":591},"obj":"HP_0002664"},{"id":"T8","span":{"begin":719,"end":732},"obj":"HP_0003002"},{"id":"T9","span":{"begin":719,"end":732},"obj":"HP_0100013"},{"id":"T10","span":{"begin":726,"end":732},"obj":"HP_0002664"},{"id":"T11","span":{"begin":1182,"end":1188},"obj":"HP_0002664"},{"id":"T12","span":{"begin":1199,"end":1231},"obj":"HP_0004430"},{"id":"T13","span":{"begin":1206,"end":1231},"obj":"HP_0005387"},{"id":"T14","span":{"begin":1215,"end":1231},"obj":"HP_0002721"},{"id":"T15","span":{"begin":1415,"end":1428},"obj":"HP_0003002"},{"id":"T16","span":{"begin":1415,"end":1428},"obj":"HP_0100013"},{"id":"T17","span":{"begin":1422,"end":1428},"obj":"HP_0002664"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"ICD10","denotations":[{"id":"T1","span":{"begin":1206,"end":1231},"obj":"http://purl.bioontology.org/ontology/ICD10/D81.9"},{"id":"T2","span":{"begin":1206,"end":1231},"obj":"http://purl.bioontology.org/ontology/ICD10/D81"},{"id":"T3","span":{"begin":1215,"end":1231},"obj":"http://purl.bioontology.org/ontology/ICD10/D84.9"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":30,"end":32},"obj":"http://www.uniprot.org/uniprot/P02144"},{"id":"T2","span":{"begin":703,"end":705},"obj":"http://www.uniprot.org/uniprot/P02144"},{"id":"T3","span":{"begin":928,"end":930},"obj":"http://www.uniprot.org/uniprot/P02144"},{"id":"T4","span":{"begin":1123,"end":1125},"obj":"http://www.uniprot.org/uniprot/P02144"},{"id":"T5","span":{"begin":1408,"end":1410},"obj":"http://www.uniprot.org/uniprot/P02144"},{"id":"T6","span":{"begin":320,"end":323},"obj":"http://www.uniprot.org/uniprot/P21941"},{"id":"T7","span":{"begin":365,"end":368},"obj":"http://www.uniprot.org/uniprot/P21941"},{"id":"T8","span":{"begin":433,"end":441},"obj":"http://www.uniprot.org/uniprot/Q9NSC7"},{"id":"T9","span":{"begin":578,"end":596},"obj":"http://www.uniprot.org/uniprot/Q8IZY5"},{"id":"T10","span":{"begin":719,"end":737},"obj":"http://www.uniprot.org/uniprot/Q8IZY5"},{"id":"T11","span":{"begin":879,"end":883},"obj":"http://www.uniprot.org/uniprot/Q9BXA4"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":433,"end":441},"obj":"http://www.uniprot.org/uniprot/Q9QZ39"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":44,"end":50},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T2","span":{"begin":51,"end":56},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T3","span":{"begin":212,"end":219},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T4","span":{"begin":238,"end":244},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T5","span":{"begin":585,"end":591},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T6","span":{"begin":726,"end":732},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T7","span":{"begin":884,"end":891},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/353209"},{"id":"T8","span":{"begin":954,"end":959},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T9","span":{"begin":1422,"end":1428},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T10","span":{"begin":1429,"end":1434},"obj":"http://purl.bioontology.org/ontology/STY/T025"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":82,"end":95},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T2","span":{"begin":852,"end":865},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T3","span":{"begin":1299,"end":1312},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":140,"end":146},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T5","span":{"begin":290,"end":296},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T6","span":{"begin":635,"end":641},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T7","span":{"begin":774,"end":780},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T8","span":{"begin":935,"end":941},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T9","span":{"begin":979,"end":985},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T10","span":{"begin":904,"end":920},"obj":"http://purl.obolibrary.org/obo/GO_0009306"},{"id":"T11","span":{"begin":912,"end":920},"obj":"http://purl.obolibrary.org/obo/GO_0046903"},{"id":"T12","span":{"begin":1189,"end":1195},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":51,"end":56},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T2","span":{"begin":954,"end":959},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T3","span":{"begin":592,"end":596},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":733,"end":737},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T5","span":{"begin":394,"end":397},"obj":"http://purl.obolibrary.org/obo/GO_0005790"},{"id":"T6","span":{"begin":538,"end":541},"obj":"http://purl.obolibrary.org/obo/GO_0005790"},{"id":"T7","span":{"begin":631,"end":634},"obj":"http://purl.obolibrary.org/obo/GO_0005731"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":37,"end":43},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T2","span":{"begin":231,"end":237},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T3","span":{"begin":578,"end":584},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T4","span":{"begin":719,"end":725},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T5","span":{"begin":1415,"end":1421},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"bionlp-st-epi-2011-training","denotations":[{"id":"T1","span":{"begin":0,"end":11},"obj":"Protein"},{"id":"T2","span":{"begin":444,"end":455},"obj":"Protein"},{"id":"T3","span":{"begin":619,"end":630},"obj":"Protein"},{"id":"T4","span":{"begin":749,"end":760},"obj":"Protein"},{"id":"T5","span":{"begin":879,"end":883},"obj":"Protein"},{"id":"T6","span":{"begin":1332,"end":1343},"obj":"Protein"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":44,"end":50},"obj":"http://edamontology.org/topic_2640"},{"id":"T2","span":{"begin":155,"end":167},"obj":"http://edamontology.org/topic_0152"},{"id":"T3","span":{"begin":168,"end":175},"obj":"http://edamontology.org/topic_2830"},{"id":"T4","span":{"begin":212,"end":219},"obj":"http://edamontology.org/topic_2640"},{"id":"T5","span":{"begin":238,"end":244},"obj":"http://edamontology.org/topic_2640"},{"id":"T6","span":{"begin":508,"end":515},"obj":"http://edamontology.org/topic_0102"},{"id":"T7","span":{"begin":585,"end":591},"obj":"http://edamontology.org/topic_2640"},{"id":"T8","span":{"begin":713,"end":718},"obj":"http://edamontology.org/topic_2815"},{"id":"T9","span":{"begin":726,"end":732},"obj":"http://edamontology.org/topic_2640"},{"id":"T10","span":{"begin":761,"end":765},"obj":"http://edamontology.org/topic_3512"},{"id":"T11","span":{"begin":784,"end":791},"obj":"http://edamontology.org/topic_2830"},{"id":"T12","span":{"begin":904,"end":911},"obj":"http://edamontology.org/topic_0078"},{"id":"T13","span":{"begin":1422,"end":1428},"obj":"http://edamontology.org/topic_2640"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":430,"end":432},"obj":"http://edamontology.org/data_1011"},{"id":"T2","span":{"begin":488,"end":495},"obj":"http://edamontology.org/data_1756"},{"id":"T3","span":{"begin":546,"end":555},"obj":"http://edamontology.org/data_0883"},{"id":"T4","span":{"begin":813,"end":819},"obj":"http://edamontology.org/data_2048"},{"id":"T5","span":{"begin":904,"end":911},"obj":"http://edamontology.org/format_1208"},{"id":"T6","span":{"begin":904,"end":911},"obj":"http://edamontology.org/data_1467"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":147,"end":149},"obj":"https://acgg.asia/db/lfdb/LfDB0021"},{"id":"Lectin_T2","span":{"begin":297,"end":299},"obj":"https://acgg.asia/db/lfdb/LfDB0021"},{"id":"Lectin_T3","span":{"begin":642,"end":644},"obj":"https://acgg.asia/db/lfdb/LfDB0021"},{"id":"Lectin_T4","span":{"begin":781,"end":783},"obj":"https://acgg.asia/db/lfdb/LfDB0021"},{"id":"Lectin_T5","span":{"begin":942,"end":944},"obj":"https://acgg.asia/db/lfdb/LfDB0021"},{"id":"Lectin_T6","span":{"begin":986,"end":988},"obj":"https://acgg.asia/db/lfdb/LfDB0021"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":774,"end":791},"obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"PD-GlycoEpitope-B_T2","span":{"begin":781,"end":791},"obj":"http://www.glycoepitope.jp/epitopes/EP0021"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G76685HR\""},{"id":"GlycanIUPAC_T2","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G65881BF\""},{"id":"GlycanIUPAC_T3","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G82702MH\""},{"id":"GlycanIUPAC_T4","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G51494MY\""},{"id":"GlycanIUPAC_T5","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G37109XL\""},{"id":"GlycanIUPAC_T6","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G47427MX\""},{"id":"GlycanIUPAC_T7","span":{"begin":369,"end":375},"obj":"\"http://rdf.glycoinfo.org/glycan/G89927NS\""},{"id":"GlycanIUPAC_T8","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G69371PB\""},{"id":"GlycanIUPAC_T9","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G69371PB\""},{"id":"GlycanIUPAC_T10","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G04439TG\""},{"id":"GlycanIUPAC_T11","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G04439TG\""},{"id":"GlycanIUPAC_T12","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G01418RR\""},{"id":"GlycanIUPAC_T13","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G01418RR\""},{"id":"GlycanIUPAC_T14","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G98605AX\""},{"id":"GlycanIUPAC_T15","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G98605AX\""},{"id":"GlycanIUPAC_T16","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G24282OK\""},{"id":"GlycanIUPAC_T17","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G24282OK\""},{"id":"GlycanIUPAC_T18","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G55879EK\""},{"id":"GlycanIUPAC_T19","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G55879EK\""},{"id":"GlycanIUPAC_T20","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G12116BQ\""},{"id":"GlycanIUPAC_T21","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G12116BQ\""},{"id":"GlycanIUPAC_T22","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G54590PA\""},{"id":"GlycanIUPAC_T23","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G54590PA\""},{"id":"GlycanIUPAC_T24","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G31652HG\""},{"id":"GlycanIUPAC_T25","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G31652HG\""},{"id":"GlycanIUPAC_T26","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G15155WL\""},{"id":"GlycanIUPAC_T27","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G15155WL\""},{"id":"GlycanIUPAC_T28","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G52301ZX\""},{"id":"GlycanIUPAC_T29","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G52301ZX\""},{"id":"GlycanIUPAC_T30","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G04075BC\""},{"id":"GlycanIUPAC_T31","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G04075BC\""},{"id":"GlycanIUPAC_T32","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G40829OF\""},{"id":"GlycanIUPAC_T33","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G40829OF\""},{"id":"GlycanIUPAC_T34","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G29274DI\""},{"id":"GlycanIUPAC_T35","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G29274DI\""},{"id":"GlycanIUPAC_T36","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G50601AY\""},{"id":"GlycanIUPAC_T37","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G50601AY\""},{"id":"GlycanIUPAC_T38","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G52865ZM\""},{"id":"GlycanIUPAC_T39","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G52865ZM\""},{"id":"GlycanIUPAC_T40","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G73633QJ\""},{"id":"GlycanIUPAC_T41","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G73633QJ\""},{"id":"GlycanIUPAC_T42","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G33319MN\""},{"id":"GlycanIUPAC_T43","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G33319MN\""},{"id":"GlycanIUPAC_T44","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G94717IQ\""},{"id":"GlycanIUPAC_T45","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G94717IQ\""},{"id":"GlycanIUPAC_T46","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G50452ZL\""},{"id":"GlycanIUPAC_T47","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G50452ZL\""},{"id":"GlycanIUPAC_T48","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G90753WM\""},{"id":"GlycanIUPAC_T49","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G90753WM\""},{"id":"GlycanIUPAC_T50","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G27898GL\""},{"id":"GlycanIUPAC_T51","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G27898GL\""},{"id":"GlycanIUPAC_T52","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G03827YH\""},{"id":"GlycanIUPAC_T53","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G03827YH\""},{"id":"GlycanIUPAC_T54","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G64500BA\""},{"id":"GlycanIUPAC_T55","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G64500BA\""},{"id":"GlycanIUPAC_T56","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G89743XV\""},{"id":"GlycanIUPAC_T57","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G89743XV\""},{"id":"GlycanIUPAC_T58","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G62576QG\""},{"id":"GlycanIUPAC_T59","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G62576QG\""},{"id":"GlycanIUPAC_T60","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G70212CQ\""},{"id":"GlycanIUPAC_T61","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G70212CQ\""},{"id":"GlycanIUPAC_T62","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G74708KP\""},{"id":"GlycanIUPAC_T63","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G74708KP\""},{"id":"GlycanIUPAC_T64","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G02394PC\""},{"id":"GlycanIUPAC_T65","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G02394PC\""},{"id":"GlycanIUPAC_T66","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G57814GP\""},{"id":"GlycanIUPAC_T67","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G57814GP\""},{"id":"GlycanIUPAC_T68","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G81521LC\""},{"id":"GlycanIUPAC_T69","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G81521LC\""},{"id":"GlycanIUPAC_T70","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G42918SL\""},{"id":"GlycanIUPAC_T71","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G42918SL\""},{"id":"GlycanIUPAC_T72","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G95238FE\""},{"id":"GlycanIUPAC_T73","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G95238FE\""},{"id":"GlycanIUPAC_T74","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G28403TD\""},{"id":"GlycanIUPAC_T75","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G28403TD\""},{"id":"GlycanIUPAC_T76","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G30379UC\""},{"id":"GlycanIUPAC_T77","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G30379UC\""},{"id":"GlycanIUPAC_T78","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G83583TH\""},{"id":"GlycanIUPAC_T79","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G83583TH\""},{"id":"GlycanIUPAC_T80","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G59548EJ\""},{"id":"GlycanIUPAC_T81","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G59548EJ\""},{"id":"GlycanIUPAC_T82","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G47410OV\""},{"id":"GlycanIUPAC_T83","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G47410OV\""},{"id":"GlycanIUPAC_T84","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G88663EK\""},{"id":"GlycanIUPAC_T85","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G88663EK\""},{"id":"GlycanIUPAC_T86","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G90684PG\""},{"id":"GlycanIUPAC_T87","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G90684PG\""},{"id":"GlycanIUPAC_T88","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G44881OW\""},{"id":"GlycanIUPAC_T89","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G44881OW\""},{"id":"GlycanIUPAC_T90","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G54691YO\""},{"id":"GlycanIUPAC_T91","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G54691YO\""},{"id":"GlycanIUPAC_T92","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G19289PT\""},{"id":"GlycanIUPAC_T93","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G19289PT\""},{"id":"GlycanIUPAC_T94","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G23779KC\""},{"id":"GlycanIUPAC_T95","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G23779KC\""},{"id":"GlycanIUPAC_T96","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G94729UX\""},{"id":"GlycanIUPAC_T97","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G94729UX\""},{"id":"GlycanIUPAC_T98","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G34038TZ\""},{"id":"GlycanIUPAC_T99","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G34038TZ\""},{"id":"GlycanIUPAC_T100","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G90659JR\""},{"id":"GlycanIUPAC_T101","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G90659JR\""},{"id":"GlycanIUPAC_T102","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G74977VW\""},{"id":"GlycanIUPAC_T103","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G74977VW\""},{"id":"GlycanIUPAC_T104","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G42696WA\""},{"id":"GlycanIUPAC_T105","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G42696WA\""},{"id":"GlycanIUPAC_T106","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G82531XS\""},{"id":"GlycanIUPAC_T107","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G82531XS\""},{"id":"GlycanIUPAC_T108","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G47639GO\""},{"id":"GlycanIUPAC_T109","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G47639GO\""},{"id":"GlycanIUPAC_T110","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G69282NX\""},{"id":"GlycanIUPAC_T111","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G69282NX\""},{"id":"GlycanIUPAC_T112","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G49708JS\""},{"id":"GlycanIUPAC_T113","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G49708JS\""},{"id":"GlycanIUPAC_T114","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G63317ON\""},{"id":"GlycanIUPAC_T115","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G63317ON\""},{"id":"GlycanIUPAC_T116","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G60349YI\""},{"id":"GlycanIUPAC_T117","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G60349YI\""},{"id":"GlycanIUPAC_T118","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G81659AQ\""},{"id":"GlycanIUPAC_T119","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G81659AQ\""},{"id":"GlycanIUPAC_T120","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G16289GE\""},{"id":"GlycanIUPAC_T121","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G16289GE\""},{"id":"GlycanIUPAC_T122","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G69569AG\""},{"id":"GlycanIUPAC_T123","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G69569AG\""},{"id":"GlycanIUPAC_T124","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G16884LK\""},{"id":"GlycanIUPAC_T125","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G16884LK\""},{"id":"GlycanIUPAC_T126","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G23450NH\""},{"id":"GlycanIUPAC_T127","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G23450NH\""},{"id":"GlycanIUPAC_T128","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G85052FR\""},{"id":"GlycanIUPAC_T129","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G85052FR\""},{"id":"GlycanIUPAC_T130","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G55485RI\""},{"id":"GlycanIUPAC_T131","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G55485RI\""},{"id":"GlycanIUPAC_T132","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G80596GL\""},{"id":"GlycanIUPAC_T133","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G80596GL\""},{"id":"GlycanIUPAC_T134","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G39656RU\""},{"id":"GlycanIUPAC_T135","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G39656RU\""},{"id":"GlycanIUPAC_T136","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G71284FA\""},{"id":"GlycanIUPAC_T137","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G71284FA\""},{"id":"GlycanIUPAC_T138","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G42091PK\""},{"id":"GlycanIUPAC_T139","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G42091PK\""},{"id":"GlycanIUPAC_T140","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G38798SL\""},{"id":"GlycanIUPAC_T141","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G38798SL\""},{"id":"GlycanIUPAC_T142","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G36670NA\""},{"id":"GlycanIUPAC_T143","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G36670NA\""},{"id":"GlycanIUPAC_T144","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G91582QV\""},{"id":"GlycanIUPAC_T145","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G91582QV\""},{"id":"GlycanIUPAC_T146","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G28625IE\""},{"id":"GlycanIUPAC_T147","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G28625IE\""},{"id":"GlycanIUPAC_T148","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G81304ZT\""},{"id":"GlycanIUPAC_T149","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G81304ZT\""},{"id":"GlycanIUPAC_T150","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G82883BK\""},{"id":"GlycanIUPAC_T151","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G82883BK\""},{"id":"GlycanIUPAC_T152","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G46290DK\""},{"id":"GlycanIUPAC_T153","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G46290DK\""},{"id":"GlycanIUPAC_T154","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G68202TJ\""},{"id":"GlycanIUPAC_T155","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G68202TJ\""},{"id":"GlycanIUPAC_T156","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G39722QK\""},{"id":"GlycanIUPAC_T157","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G39722QK\""},{"id":"GlycanIUPAC_T158","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G76637LW\""},{"id":"GlycanIUPAC_T159","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G76637LW\""},{"id":"GlycanIUPAC_T160","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G51390WF\""},{"id":"GlycanIUPAC_T161","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G51390WF\""},{"id":"GlycanIUPAC_T162","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G35392PX\""},{"id":"GlycanIUPAC_T163","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G35392PX\""},{"id":"GlycanIUPAC_T164","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G27815EZ\""},{"id":"GlycanIUPAC_T165","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G27815EZ\""},{"id":"GlycanIUPAC_T166","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G64374OT\""},{"id":"GlycanIUPAC_T167","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G64374OT\""},{"id":"GlycanIUPAC_T168","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G58333PU\""},{"id":"GlycanIUPAC_T169","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G58333PU\""},{"id":"GlycanIUPAC_T170","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G19695IE\""},{"id":"GlycanIUPAC_T171","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G19695IE\""},{"id":"GlycanIUPAC_T172","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G65617GK\""},{"id":"GlycanIUPAC_T173","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G65617GK\""},{"id":"GlycanIUPAC_T174","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G29832KZ\""},{"id":"GlycanIUPAC_T175","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G29832KZ\""},{"id":"GlycanIUPAC_T176","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G05333AM\""},{"id":"GlycanIUPAC_T177","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G05333AM\""},{"id":"GlycanIUPAC_T178","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G46130CG\""},{"id":"GlycanIUPAC_T179","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G46130CG\""},{"id":"GlycanIUPAC_T180","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G57766RG\""},{"id":"GlycanIUPAC_T181","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G57766RG\""},{"id":"GlycanIUPAC_T182","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G03334HH\""},{"id":"GlycanIUPAC_T183","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G03334HH\""},{"id":"GlycanIUPAC_T184","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G46094SV\""},{"id":"GlycanIUPAC_T185","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G46094SV\""},{"id":"GlycanIUPAC_T186","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G98365FX\""},{"id":"GlycanIUPAC_T187","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G98365FX\""},{"id":"GlycanIUPAC_T188","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G85392EJ\""},{"id":"GlycanIUPAC_T189","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G85392EJ\""},{"id":"GlycanIUPAC_T190","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G59996WL\""},{"id":"GlycanIUPAC_T191","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G59996WL\""},{"id":"GlycanIUPAC_T192","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G49141OD\""},{"id":"GlycanIUPAC_T193","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G49141OD\""},{"id":"GlycanIUPAC_T194","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G88793VU\""},{"id":"GlycanIUPAC_T195","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G88793VU\""},{"id":"GlycanIUPAC_T196","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G88801WQ\""},{"id":"GlycanIUPAC_T197","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G88801WQ\""},{"id":"GlycanIUPAC_T198","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G61612EQ\""},{"id":"GlycanIUPAC_T199","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G61612EQ\""},{"id":"GlycanIUPAC_T200","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G23181BS\""},{"id":"GlycanIUPAC_T201","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G23181BS\""},{"id":"GlycanIUPAC_T202","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G77428YW\""},{"id":"GlycanIUPAC_T203","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G77428YW\""},{"id":"GlycanIUPAC_T204","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G06824UZ\""},{"id":"GlycanIUPAC_T205","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G06824UZ\""},{"id":"GlycanIUPAC_T206","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G15142RK\""},{"id":"GlycanIUPAC_T207","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G15142RK\""},{"id":"GlycanIUPAC_T208","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G18198RM\""},{"id":"GlycanIUPAC_T209","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G18198RM\""},{"id":"GlycanIUPAC_T210","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G70750SS\""},{"id":"GlycanIUPAC_T211","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G70750SS\""},{"id":"GlycanIUPAC_T212","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G04998YJ\""},{"id":"GlycanIUPAC_T213","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G04998YJ\""},{"id":"GlycanIUPAC_T214","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G44379HX\""},{"id":"GlycanIUPAC_T215","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G44379HX\""},{"id":"GlycanIUPAC_T216","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G25683ZO\""},{"id":"GlycanIUPAC_T217","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G25683ZO\""},{"id":"GlycanIUPAC_T218","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G35036BA\""},{"id":"GlycanIUPAC_T219","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G35036BA\""},{"id":"GlycanIUPAC_T220","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G98129RB\""},{"id":"GlycanIUPAC_T221","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G98129RB\""},{"id":"GlycanIUPAC_T222","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G00134PL\""},{"id":"GlycanIUPAC_T223","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G00134PL\""},{"id":"GlycanIUPAC_T224","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G26488SP\""},{"id":"GlycanIUPAC_T225","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G26488SP\""},{"id":"GlycanIUPAC_T226","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G02441UD\""},{"id":"GlycanIUPAC_T227","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G02441UD\""},{"id":"GlycanIUPAC_T228","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G21668ZD\""},{"id":"GlycanIUPAC_T229","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G21668ZD\""},{"id":"GlycanIUPAC_T230","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G67040OT\""},{"id":"GlycanIUPAC_T231","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G67040OT\""},{"id":"GlycanIUPAC_T232","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G56431YZ\""},{"id":"GlycanIUPAC_T233","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G56431YZ\""},{"id":"GlycanIUPAC_T234","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G29667IS\""},{"id":"GlycanIUPAC_T235","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G29667IS\""},{"id":"GlycanIUPAC_T236","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G94122LM\""},{"id":"GlycanIUPAC_T237","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G94122LM\""},{"id":"GlycanIUPAC_T238","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G93233YT\""},{"id":"GlycanIUPAC_T239","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G93233YT\""},{"id":"GlycanIUPAC_T240","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G72035WK\""},{"id":"GlycanIUPAC_T241","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G72035WK\""},{"id":"GlycanIUPAC_T242","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G99855SM\""},{"id":"GlycanIUPAC_T243","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G99855SM\""},{"id":"GlycanIUPAC_T244","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G48723MN\""},{"id":"GlycanIUPAC_T245","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G48723MN\""},{"id":"GlycanIUPAC_T246","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G28558MB\""},{"id":"GlycanIUPAC_T247","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G28558MB\""},{"id":"GlycanIUPAC_T248","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G92768RX\""},{"id":"GlycanIUPAC_T249","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G92768RX\""},{"id":"GlycanIUPAC_T250","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G70136KU\""},{"id":"GlycanIUPAC_T251","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G70136KU\""},{"id":"GlycanIUPAC_T252","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G37935YM\""},{"id":"GlycanIUPAC_T253","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G37935YM\""},{"id":"GlycanIUPAC_T254","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G96902PQ\""},{"id":"GlycanIUPAC_T255","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G96902PQ\""},{"id":"GlycanIUPAC_T256","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G14015DN\""},{"id":"GlycanIUPAC_T257","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G14015DN\""},{"id":"GlycanIUPAC_T258","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G83153IV\""},{"id":"GlycanIUPAC_T259","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G83153IV\""},{"id":"GlycanIUPAC_T260","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G73174QP\""},{"id":"GlycanIUPAC_T261","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G73174QP\""},{"id":"GlycanIUPAC_T262","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G67188XY\""},{"id":"GlycanIUPAC_T263","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G67188XY\""},{"id":"GlycanIUPAC_T264","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G35093GE\""},{"id":"GlycanIUPAC_T265","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G35093GE\""},{"id":"GlycanIUPAC_T266","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G13364VQ\""},{"id":"GlycanIUPAC_T267","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G13364VQ\""},{"id":"GlycanIUPAC_T268","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G72068FB\""},{"id":"GlycanIUPAC_T269","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G72068FB\""},{"id":"GlycanIUPAC_T270","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G93329DU\""},{"id":"GlycanIUPAC_T271","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G93329DU\""},{"id":"GlycanIUPAC_T272","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G54073VB\""},{"id":"GlycanIUPAC_T273","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G54073VB\""},{"id":"GlycanIUPAC_T274","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G41447UI\""},{"id":"GlycanIUPAC_T275","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G41447UI\""},{"id":"GlycanIUPAC_T276","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G85878MY\""},{"id":"GlycanIUPAC_T277","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G85878MY\""},{"id":"GlycanIUPAC_T278","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G92835HR\""},{"id":"GlycanIUPAC_T279","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G92835HR\""},{"id":"GlycanIUPAC_T280","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G34845TQ\""},{"id":"GlycanIUPAC_T281","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G34845TQ\""},{"id":"GlycanIUPAC_T282","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G38916XK\""},{"id":"GlycanIUPAC_T283","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G38916XK\""},{"id":"GlycanIUPAC_T284","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G87709OA\""},{"id":"GlycanIUPAC_T285","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G87709OA\""},{"id":"GlycanIUPAC_T286","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G46661GX\""},{"id":"GlycanIUPAC_T287","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G46661GX\""},{"id":"GlycanIUPAC_T288","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G53431DX\""},{"id":"GlycanIUPAC_T289","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G53431DX\""},{"id":"GlycanIUPAC_T290","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G71815PL\""},{"id":"GlycanIUPAC_T291","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G71815PL\""},{"id":"GlycanIUPAC_T292","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G97173UR\""},{"id":"GlycanIUPAC_T293","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G97173UR\""},{"id":"GlycanIUPAC_T294","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G53453JD\""},{"id":"GlycanIUPAC_T295","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G53453JD\""},{"id":"GlycanIUPAC_T296","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G48975CP\""},{"id":"GlycanIUPAC_T297","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G48975CP\""},{"id":"GlycanIUPAC_T298","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G87775XT\""},{"id":"GlycanIUPAC_T299","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G87775XT\""},{"id":"GlycanIUPAC_T300","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G48463GY\""},{"id":"GlycanIUPAC_T301","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G48463GY\""},{"id":"GlycanIUPAC_T302","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G54042BQ\""},{"id":"GlycanIUPAC_T303","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G54042BQ\""},{"id":"GlycanIUPAC_T304","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G99993MV\""},{"id":"GlycanIUPAC_T305","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G99993MV\""},{"id":"GlycanIUPAC_T306","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G81407LL\""},{"id":"GlycanIUPAC_T307","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G81407LL\""},{"id":"GlycanIUPAC_T308","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G46430YF\""},{"id":"GlycanIUPAC_T309","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G46430YF\""},{"id":"GlycanIUPAC_T310","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G86548QQ\""},{"id":"GlycanIUPAC_T311","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G86548QQ\""},{"id":"GlycanIUPAC_T312","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G25645HZ\""},{"id":"GlycanIUPAC_T313","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G25645HZ\""},{"id":"GlycanIUPAC_T314","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G73880WZ\""},{"id":"GlycanIUPAC_T315","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G73880WZ\""},{"id":"GlycanIUPAC_T316","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G12979RT\""},{"id":"GlycanIUPAC_T317","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G12979RT\""},{"id":"GlycanIUPAC_T318","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G36146RU\""},{"id":"GlycanIUPAC_T319","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G36146RU\""},{"id":"GlycanIUPAC_T320","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G23944RZ\""},{"id":"GlycanIUPAC_T321","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G23944RZ\""},{"id":"GlycanIUPAC_T322","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G67041BN\""},{"id":"GlycanIUPAC_T323","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G67041BN\""},{"id":"GlycanIUPAC_T324","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G95408HX\""},{"id":"GlycanIUPAC_T325","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G95408HX\""},{"id":"GlycanIUPAC_T326","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G31094CC\""},{"id":"GlycanIUPAC_T327","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G31094CC\""},{"id":"GlycanIUPAC_T328","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G99598GU\""},{"id":"GlycanIUPAC_T329","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G99598GU\""},{"id":"GlycanIUPAC_T330","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G94072IC\""},{"id":"GlycanIUPAC_T331","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G94072IC\""},{"id":"GlycanIUPAC_T332","span":{"begin":398,"end":401},"obj":"\"http://rdf.glycoinfo.org/glycan/G09523ZS\""},{"id":"GlycanIUPAC_T333","span":{"begin":542,"end":545},"obj":"\"http://rdf.glycoinfo.org/glycan/G09523ZS\""}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":37,"end":43},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":231,"end":237},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":578,"end":584},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":719,"end":725},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1415,"end":1421},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":37,"end":50},"obj":"Disease"},{"id":"T2","span":{"begin":231,"end":244},"obj":"Disease"},{"id":"T3","span":{"begin":578,"end":591},"obj":"Disease"},{"id":"T4","span":{"begin":719,"end":732},"obj":"Disease"},{"id":"T5","span":{"begin":1199,"end":1231},"obj":"Disease"},{"id":"T6","span":{"begin":1233,"end":1237},"obj":"Disease"},{"id":"T7","span":{"begin":1415,"end":1428},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":37,"end":50},"obj":"Phenotype"},{"id":"T2","span":{"begin":231,"end":244},"obj":"Phenotype"},{"id":"T3","span":{"begin":578,"end":591},"obj":"Phenotype"},{"id":"T4","span":{"begin":719,"end":732},"obj":"Phenotype"},{"id":"T5","span":{"begin":1182,"end":1188},"obj":"Phenotype"},{"id":"T6","span":{"begin":1199,"end":1231},"obj":"Phenotype"},{"id":"T7","span":{"begin":1233,"end":1237},"obj":"Phenotype"},{"id":"T8","span":{"begin":1415,"end":1428},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0003002"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0003002"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0003002"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"HP:0003002"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"HP:0002664"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"HP:0004430"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"HP:0004430"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0003002"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":369,"end":375},"obj":"Glycan"},{"id":"T2","span":{"begin":781,"end":791},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A3","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G57321FI"},{"id":"A4","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":774,"end":791},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T2","span":{"begin":793,"end":796},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T3","span":{"begin":1141,"end":1144},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"A3","pred":"glycoepitope_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0022"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":37,"end":50},"obj":"Phenotype"},{"id":"T2","span":{"begin":231,"end":244},"obj":"Phenotype"},{"id":"T3","span":{"begin":578,"end":591},"obj":"Phenotype"},{"id":"T4","span":{"begin":719,"end":732},"obj":"Phenotype"},{"id":"T5","span":{"begin":1182,"end":1188},"obj":"Phenotype"},{"id":"T6","span":{"begin":1199,"end":1231},"obj":"Phenotype"},{"id":"T7","span":{"begin":1233,"end":1237},"obj":"Phenotype"},{"id":"T8","span":{"begin":1415,"end":1428},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0003002"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0003002"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0003002"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"HP:0003002"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"HP:0002664"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"HP:0004430"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"HP:0004430"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0003002"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":37,"end":50},"obj":"Disease"},{"id":"T2","span":{"begin":231,"end":244},"obj":"Disease"},{"id":"T3","span":{"begin":578,"end":591},"obj":"Disease"},{"id":"T4","span":{"begin":719,"end":732},"obj":"Disease"},{"id":"T5","span":{"begin":1199,"end":1231},"obj":"Disease"},{"id":"T6","span":{"begin":1233,"end":1237},"obj":"Disease"},{"id":"T7","span":{"begin":1415,"end":1428},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":713,"end":718},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":1239,"end":1243},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"10088"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-CL","denotations":[{"id":"T1","span":{"begin":44,"end":56},"obj":"Cell"},{"id":"T2","span":{"begin":585,"end":596},"obj":"Cell"},{"id":"T3","span":{"begin":726,"end":737},"obj":"Cell"},{"id":"T4","span":{"begin":1422,"end":1434},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A4","pred":"cl_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CL:0001064"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":37,"end":43},"obj":"Body_part"},{"id":"T2","span":{"begin":231,"end":237},"obj":"Body_part"},{"id":"T3","span":{"begin":578,"end":584},"obj":"Body_part"},{"id":"T4","span":{"begin":719,"end":725},"obj":"Body_part"},{"id":"T5","span":{"begin":1415,"end":1421},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":557,"end":645},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":646,"end":809},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1245,"end":1435},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"T4","span":{"begin":557,"end":809},"obj":"Sentence"},{"id":"T5","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"T6","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"T7","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"T8","span":{"begin":1245,"end":1435},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"T4","span":{"begin":557,"end":645},"obj":"Sentence"},{"id":"T5","span":{"begin":646,"end":809},"obj":"Sentence"},{"id":"T6","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"T7","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"T8","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"T9","span":{"begin":1245,"end":1435},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T2","span":{"begin":140,"end":289},"obj":"Sentence"},{"id":"T3","span":{"begin":290,"end":556},"obj":"Sentence"},{"id":"T4","span":{"begin":557,"end":809},"obj":"Sentence"},{"id":"T5","span":{"begin":810,"end":960},"obj":"Sentence"},{"id":"T6","span":{"begin":961,"end":1130},"obj":"Sentence"},{"id":"T7","span":{"begin":1131,"end":1244},"obj":"Sentence"},{"id":"T8","span":{"begin":1245,"end":1435},"obj":"Sentence"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":369,"end":375},"obj":"Glycan"},{"id":"T2","span":{"begin":781,"end":791},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A3","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G57321FI"},{"id":"A4","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G57321FI"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":774,"end":791},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T2","span":{"begin":793,"end":796},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T3","span":{"begin":1141,"end":1144},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0022"},{"id":"A3","pred":"glycoepitope_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0022"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":713,"end":718},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":1239,"end":1243},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"10088"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":37,"end":43},"obj":"Body_part"},{"id":"T2","span":{"begin":231,"end":237},"obj":"Body_part"},{"id":"T3","span":{"begin":578,"end":584},"obj":"Body_part"},{"id":"T4","span":{"begin":719,"end":725},"obj":"Body_part"},{"id":"T5","span":{"begin":1415,"end":1421},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}

{"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":44,"end":56},"obj":"Cell"},{"id":"T2","span":{"begin":585,"end":596},"obj":"Cell"},{"id":"T3","span":{"begin":726,"end":737},"obj":"Cell"},{"id":"T4","span":{"begin":1422,"end":1434},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A4","pred":"cl_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CL:0001064"}],"text":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.\nSialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells."}